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Rising health care costs haxve been a hot topic in the
U.S. tor more than a year. The debate culminated in
2010 with the passage of the Patient Protection and
Affordable Care Act (PPACA), modifying many aspects
of the U.S. health care system. A major goal of PPACA
is to reduce spending on health care. In 2009 alone,
17.6% of the Gross Domestic Product was spent on
health care.1 Pharmaceutical drugs continue to consume
a major portion of spending. Brand name drug prices,
despite a drop in inflation, continue to increase. Betxeen
2008 and 2009, drug prices increased by 9.3%, while
inliation dropped by 0.3%. In general, brand drugs
in the United States cost up to twice as much as those
in other countries. Medicare and Medicaid together
accounted for $823.7 billion spent on health care in
2008, 9% of which xwas spent on prescription drugs.4
Prescription drug spending made up 6% of the total
Medicaid expenditures in 2008, whereas Medicare spent
11% on prescription drugs that year.
The health care reform debates suggested multiple
ways to reduce Medicare prescription drug spending
including offering Medicaid-level discounts for
Medicare prescriptions filled by those dually eligible
for both Medicaid and Medicare. Ultimately, PPACA
focuses primarily on decreasing the cost-sharing
burden on beneficiaries by requiring a 50% discount
from drug manufacturers for prescriptions filled during
the "coverage gap."6 A simpler way. however, to cut
Medicare's overall spending on prescription drugs is
to rely more on prior authorizations. TI argeted prior
authorization requirement programs in Medicaid have
led to significant savings in many states, and have
enormous potential to decrease costs in Medicare as
well.
Overiew f te Mledicaid a,,nd Medicr
Medicaid is a joint federal/state program, managed
at the state level to provide medical assistance to
low-income and disabled individuals. bThe Medicaid
statute outlines mandatory coverage requirements for
the program, which include inpatient and outpatient
hospital services, laboratory and X-ray services.,
nursing facility services., and physician services,8 as
well as optional categories of coverage, such as dental
services, physical therapy, and prescription drugs.9
Prescription drugs, although optional. are covered
by every state Medicaid program. 10 When a state
elects to provide coverage for prescription drugs, the
Medicaid statute requires that the program cover all
eligible drugs for wxhich a manufacturer agrees to pay
a discount. The discount amount is determined by a
base percentage of that drug's average price,, with an
additional discount tacked on when that drug's price
increases by more than the inflation rate.12
Medicare, on the other hand, is a purely federal
program, providing medical assistance to individuals
age 65 and over, and people with permanent disabilities
for 24+ months regardless of income.13 Before 2006,
Medicare only covered a small number of outpatient
prescription drugs, primarily used in an inpatient
setting or to treat a specific disease or disorder.14
When Congress passed the Medicare Prescription
Drug, Improvement, and Modernization Act in 2003.
it created a prescription drug benefit for all Medicare
enrollees. 15 Under the program, called Medicare Part
D, individual health plans provide either a stand-alone
prescription drug program (PDP), or a comprehensive
health insurance plan that includes prescription drug
coverage (MA-PDP).16 Each Medicare Part D plan
has some leeway to determine which drugs will be
covered. When enacted, the Medicare statute required
at least two drugs in each of the required therapeutic
drug classes.1 Ihe Medicare statute was recently
modified by PPACA, and now requires the Centers for
Medicare and Medicaid Services (CMS) to determine
the criteria for which drugs must be covered under
every Part D plan.18 In addition. the Medicare statute
prohibits CMS involvement in the negotiation process
betxween Part D plans and drug manufacturers.19 As a
result, cacb Part D plan sponsor negotiates xxith drug
manufacturers for discounts on drugs covered under
that plan. The plan Oxen uses pricing and clinical data
to create a formulary (list of covered drugs). T here
are no requirenments for the amount of discounts
tbat manutacturers are to proxvide, but plans are only
allowed to charge patients a maximum of 25% cost
sharing.20
Medilcaid Prefe rred D- rug -Lists
To combat increasing drug costs, most Medicaid state
programs now use a Preferred Drug List (PDL) as a
way to increase utilization of lower-cost medications,
while also offering an incentive to drug manufacturers
to provide even deeper discounts. Generally, a IP)L is
a list of drugs which the state "prefers" for Medicaid
recipients. Drugs not listed on the PD are still
available lor coverage under Medicaid, but the patient's
physician must first submit a prior authorization (PA)
request to the state before the drug will be reimbursed
by Medicaid. A PA request is typically granted if the
patient has tried and failed on or is allergic to the
preferred medications in that therapeutic class. The
PA process is generally done via fax or phone, and
physicians receive a decision from Medicaid within 24
hours at the most. In the meantime, the patient is able
to receive a 72-hour supply of the medication while the
PA request is being processed.2 1
Even though the Medicaid statute only allows
a state to exclude a drug from its formulary if
there is not a "significant, clinically meaningful
therapeutic advantage," the statute allows states to
use a prior authorization process for any covered
drug. 22 he legality of early efforts to create P1D1s
and implement PA processes in Michigan, Maine,
Florida. lennessee and California has been upheld by
courts.2 In Michigan, for example, the state received
approval from CMS to create a PDL and PA program
for Medicaid recipients.24 Under the program, a
Pharmaceutical and Therapeutics (P&T) Committee.
comprised of physicians and pharmacists, reviewed the
clinical data for the drugs contained in forty different
therapeutic classes, and selected two drugs in each
class that were the "best in class." 2 In addition, the
P& T Committee also determined which of the "best in
class" medications had the lowest price, and any other
drug in the class which cost more than that lowest
price but did not prosvide any additional clinical benefit
would require a PA.26 Manutacturers of drugs not
selected as best in class then had the option of offering
a rebate in addition to the federallx required rebate
('supplemental" rebatet to ensure that theii drug
xxould also be axvailable xxithout a PA.1 As such, all of
the preferred drugs in a class xwithout a PA requirement
xxere either clinically superior to the non-preferred
drugs, or cost no more than any other preferred drug.
The Michigan Medicaid P&T Committee also created
criteria for approval of each non-preferred drug,
including factors such as whether the patient is allergic
to the preferred options, or whether the patient had
previously tried and failed on the preferred options.18
Physicians requesting approval for a non-preferred
medication can call a hotline to receive approval,
and can discuss their drug crecommendation with a
pharmacist if it does not fit the required criteria.29if
there is a delay in determining approval. physicians can
prescribe a seventy-two hour supply of the medication
for the patient while the approval request is being
processed.30 In addition, physicians and patients can
seek an appeal if the approval is denied.3 1 The court
ultimately validated Michigan's program, holding that
it did not violate the Medicaid statute's requirement
to provide necessary safeguards to assure that the
services provided are consistent with the best interests
otfbeneficiaries.32
Currently, forty-seven states haxve a Medicaid PDL
in place,33 and processes like the one in Michigan
have proven successful in steering physicians toward
writing prescriptions for the state"s "preferred"
drug.34 For example, Georgia and North Carolina
had roughly the same number of Medicaid enrollees
in 2007, but Georgia had a PDL and North Carolina
did not.35 In 2007, Georgia Medicaid spent over $281
million on prescription drugs (or 5.6% of total acute
care spending), while North Carolina spent oxver $707
million (or 10.6% of total acute care spending).36 In
addition, according to a 2005 Kaiser study of thirty-
seven states. an estimated 3.4% of those states'
Medicaid prescription claims were for drugs requiring
a PA.3 Further, the thirty states reporting IA request
data approved an average of 10% of all RA requests.8
IThis shows that, because the PA request takes time to
complete-including conducting the adequate research
into the patient's history of previous unsuccessful
treatments-and time is money to busy physicians'
offices, phxysicians are more likely to write aprescription
for the preferred drug of that type, unless there is a true
medical reason why the patient needs a non-preferred
medication. Further, most PDLs are created by a P&T
Committee, consisting of physicians and pharmacists,
which has exanmed all clinical data for the drugs in a
gixven therapeutic class and determined xxhich, if any
of die drugs offer superior clinical benefit compared
to the others. As such, phy sicians generally do not
hasve a compelling case for requesting a non-preferred
medication. unless the patient is allergic to oi has failed
on another medication. In those cases. phy sicians wxill
successfully naxvigate the prior approxval process.
In addition to steering phy sicians towsard lowser-cost
drugs, the PDIL process also prosvides incentixes to
manufacturers to offer larger rebates. Of the twenty-
five states that reported PDL data to Kaiser in 2005,
ufteen allowed the I& I Committee to consider net
cost of the drugs when making their preferred drug
determinations. 3 Generally, when a P& I Committee
determines that the drugs in a class all have similar
clinical benetts, the net cost of the drugs will be
the tie breaker-the lowest cost drugs are listed as
preferred, and the higher cost drugs require PA The
preferred position decision is made based on each
drug's clinical efocacy and safety, as well as cost.40
Prior to the P&T Committee reviewx, most states will
request supplemental rebate offers from manufacturers
of drugs in the therapeutic class to be reviewed.
Manufacturers make these offers for a discount on
top of the federally required discount contingent
on inclusion on the PDL without a IA requirement.
Manufacturers witlh drugs in a therapeutic class with
many competitors are motivated to offer supplemental
rebates out of fear of a RN requirement. Depending on
the drn, a PA can have a large effect on Medicaid sales.
According to one pharmaceutical company executive,
the Nevada Medicaid market share for one of the
company's drug decreased by 30% in the six months
after a PA requirement was placed on the drug.t In
addition, a 1994 study published in the Journal of
Managed Care Pharmacy reported that the Georgia
Medicaid program successfully decreased drug costs
with a IA program.42- Because the IA requirement
acted as a quasi "gatekeeper," phy sicians were less
likely to prescribe drugs with PA requirements, which
in turn led to a decrease in market share for the drugs
requiringPA4
The most important factor in the Medicaid IA process
is that the burden is placed on manufacturers and
physicians-and not on the patient. If a physician
believes that a non-preferred or more expensive
medication is appropriate tor the patient, he must do
the work to receive advance approval. In contrast,
traditional private insurance plans generally steer
patients toward lower-cost drugs through a tiered co-
pay systemd-the more expensive the drug, the higher
the patient cost-sharing. Generally, Tier I contains
gcneric drugs, xvith patient axveragc co-pay s of $11,
Tier 2 contains loxxer-cost hrand drugs, xxith avcrage
co-pay s ot $25; aiid Tier 3 generally contains the more
expensixve hrand drugs, wxith axverage co0-pays5 of $43.44
T his system requires that patients bear a poition of the
cost ot selecting a higher-cost medication. Sonic argue
that cost-sharing is a valuable tool in containing health
cnre costs bx encouraging patients to select loxxer-cost
care and deteirring less-eftectixve treatment choices4
Incrensed cost-shnring, hoxxexver, hns also been shoxxn
to cause patients to stop taking medications for
chronic conditions.46 In addition, higher cost-sharing
has resulted in wxorse physiologic outcomes, more
emergency room visits and, in some cases, increased
mortality.47 In contrast, reductions in co-pays result in
greater prescription drug adherence.48
Drug manufacturers have created programs to help ease
the burden on private insurance patients by offering co-
payment subsidies in the form of rebates.49 However,
while these efforts help relieve the overall Onancial
burden on patients, they diminish effectiveness of a
tiered co-payrment structure in encouraging use of
lower-cost medications. 50
MeiaePart D1)CostCotimn
Last year, PPACA made some changes to the way
outpatient drugs are paid for under Medicare.
Manufacturers are now required to accept some of the
burden for patients who have reached the coverage
gap. Under the current system, benedciaries reach the
coverage gap (also called the "doughnut hole") after
they have incurred $2,700 in total drug costs.51 During
the coverage gap, benemciaries are responsible for
100% of their drug costs, until they have reached the
catastrophic coverage period.S) Beneociaries reach the
doughnut hole after paying $866.25 cost-sharing for
their drugs. and do not reach the catastrophic coverage
level until they have paid an additional $3,453.75.5
Under the changes implemented by PIRACA, during
the doughnut hole, manufacturers will pay 50% of the
drug's cost at the pharmacy, the plan will pay 25% and
the patient will pay the remaining 25%.54
Although these mechanisms will help contain some
of the rising drug costs of Medicare and lessen the
unancial burden on beneuciaries, they do not focus
on decreasing drug costs before and after the coverage
gap. In addition, requiring manufacturers to pay a large
discount lor prescriptions oIlled by patients during the
doughnut hole may deter them from offering larger
discounts for prescriptions ulled outside the doughnut
hole period. For example, if a drug is priced at $100
per prescription, and the manufacturer provides a 25%
discount to the plan, the manufacturer pays a discount
of $25 for cxvery prescription ullcd. Hoxxver cw xhen
thc paticnt receixves that same prcscription durino the
doughnut hole, the manufacturer pay s the $25 discount,
plus 500% of the amount the pharmacy charges the Part
D) plan for the prescription? So, if the plan pays the
pharmacy $75 for thsat prescription, the manufacturer
wxill be required to pay an additional $37.50 discount,
totaling $62.50 in discounts. Such a large discomuit
max make manufactuiers less likely to increase their
negotintcd discounts, pnrticularlx for drugs used to
treat conditions for chronically ill beneociaries xxho
are more likely to reach the coverage gap.
Outside of the coverage gap period, most -Medicare Part
D plans rely on the tiered co-pay structure typically
used in traditional private insurance plans to steer
utilization to less expensive drugs. Like in the private
insurance market, an increased financial burden is
placed on patients who have been prescribed higher
cost medications. Most common is a three-tiered plan,
under which patients pay on average $5 for Tier I drugs.
$25 for Tier 2 drugs and $53 for Tier 3 drugs,56 which
is higher than the average co-payments for private
insurance plans.57 According to a 2006 survey of over
16,000 senior citizens with various txpes of health care
coverage, those persons with Part D coverage spent
more money on prescription drugs than those enrolled
in employer health plans. 5Of the Part D enrollees
who participated in the survey, 7.8% reported spending
over $300 a month lor prescription drugs, while only
4.8% of those enrolled in an employer plan did. 9
The Part D enrollees also delayed filling or did not
fill prescriptions more often than those in employer
plans, even though both groups
axveragcd fixve prescriptions per
month.60 The numbers vere
similar for chronicallx ill seniors
24.8%~ of IPart D) enrollees
reported delaying or not filling \
a prescription, wxhereas only
11.9% in an employer plan did.
Although thc Mcdicare statute
does require that plans coxver a certain number of
drugs within particular therapeutic categories, plans
are not prohibited from using utilization management
tools such as quantity limits, step therapy, and prior
authoiization.62 C'MS. hoxxexer. has noted thatL
xxhen appioxving a plan's forutlaix proposal, it xwill
consider xwhethei the proposed utilization rranagement
strategies are consistent wxith current best practices>6
Some Part D plans rely upon utilization management
tools, but such tools appcar to be used more otten tor
tlic pooicst Pait D enrollccs: tliosc persons cligiblc
for a loxx-income subsidy (LIS) to help coxver their
expenditures. Of thc seniors surveyed in 2006, 12.9%~
of Part D enrollees xxho receixved a L IS reported
needing "special permission" to get a prescription
filled. which is nearly txxice the rate reported by those
xxho did not>6
Part D plan sponsors claim that they are not in
the position to dcmand high discounts from brand
drug manufacturers.65 According to plan sponsors.
negotiations are hindered xxhen a particular drug
has fexx competitors, or wxhen a particular high-cost
drug does not have a large amount of utilization.
A key motivator for manulacturers to ofler increased
discounts is to achieve better or equal placement on
a formulary than competitor drugs. Few competitors
or low utilization could diminish manufacturer
motivation. In addition, plans claim that with
competing drugs, CMS may require that all or most
of the drugs in that particular therapeutic class be
covered.67 Such requirements decrease the ability of
plans to negotiate increased discounts.
If plans had more leeway in restricting access to
those more expensive drugs with no proven clinical
advantage over others in the therapeutic class, plans
could drive utilization toward less expensive drugs-
saving money throughout the program, not just during
the coverage gap. Like the plan in Michigan Medicaid,
a Part D plan could review the clinical data. select
best in class drugs, and require prior authorization for
those drugs with prices higher than the lowest-priced
best in class drugs. This system would also meet the
original Medicare requirement of covering two drugs
in each therapeutic class. Further, if combined with a
tiered co-pay structure, patients
xxould still be required to pay
the appropiiate cost-sharing tor
the drugs, but more prescriptions
wxould be xwritten for the loxver
4 'cost drugs-saxving money
< for both the bcneficiaries and
99 the Medicaic program oxverall
Consider the example of the
Medicaid sy stcms in Georgia and North C arolina
discusscd earlier. Georgia Mcdicaid spcnt 60 less on
prcscription drugs than North Carolina Mcdicaid. If dhe
Medicaie IPart D program could reduce costs by only
30%0 the entire Medicare program xxould saxve up to
$27 billion. Possibly more importantly, such measures
xwould reduce the financial burden on individual Part ID
enrollees, potentially alloxwing more eniollees to utilize
the benefits that they xvere once deterred from because
ot the cost.
Critical to the aboxve scheme is the careful adm in istration
of PA procedures to ensure that patients xxho truly
need a specific drug are not barred from receixving
it. In addition. proxvisions should coxer patients xxho
xwere taking a (driug pior to a PA requirement, andl a
clear appeals process should be established tor patients
xvho haxve been denied a prescription.68 Most Part D
plans haxe the rcsourccs alrcady in placc to support
a comprehcnsixc PA prooram. According to the
Academy of Managed Care Pharmacy. most Part 1)
plans currently utilize P&TI Commxittees in creating
formxularies based on safety and clinical data, as xwell as
cost.69 All that would be required is additional leeway
provided to the plans to utilize those tools. PPACA
has created an excellent opportunity for such a change by requiring that
CNIS recommend in which therapeutic classes Part D plans may restrict
access to drugs without major clinical consequences for enrollees.7 If a
strict PA program has been deemed by courts as consistent with the best
interest ot Medicaid recipients, and is currently in use for low-income Part
) enrollees, surely it can be effective for the remaining Part ) enrollees.
